SOSEI, HRA, AND SANDOZ/HEXAL AUSTRALIA TO CONCLUDE SUBLICENSING AGREEMENT FOR "MORNING AFTER PILL" SOH-075

Japanese biopharmaceutical company Sosei has announced that it and French pharmaceutical Laboratoire HRA Pharma (HRA) have entered into a sublicensing agreement with Sandoz/Hexal Australia, a wholly owned subsidiary of Novartis AG, for the distribution of SOH-075, an oral levonorgestrel emergency contraceptive developed by HRA. Under the agreement terms, Sandoz Hexal will be licensed to distribute SOH-075 in Australia. Orally administered within 72 hours after an unprotected sexual intercourse, the drug can prevent pregnancy.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=11564)